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The rate-limiting step in the formation of prostanoids is the conversion of arachidonic acid to prostaglandin H, by cyclooxygenase, also known 
as prostaglandin G/H synthase/cyclooxygenase. Two forms of cyclooxygenase have been characterized: a ubiquitously expressed form (COX-1) 
and a recently described second form (COX-2) inducible by various factors including mitogens, hormones, serum and cytokines. Here we quantitate 
by the reverse transcriptase-polymerase chain reaction (RT-PCR) the expression of COX-1 and COX-2 mRNA in human tissues including lung, 
uterus, testis, brain, pancreas, kidney, liver, thymus, prostate, mammary gland, stomach and small intestine. All tissues examined contained both 
COX-1 and COX-2 mRNA and could be grouped according to the level of COX mRNA expression. The highest levels of COX mRNAs were 
detected in the prostate where approximately equal levels of COX-1 and COX-2 transcripts were present. In the lung high levels of COX-2 were 
observed whereas COX-1 mRNA levels were about 2-fold lower. An intermediate level of expression of both COX-1 and COX-2 mRNA was 
observed in the mammary gland, stomach, small intestine, and uterus. The lowest levels of COX-1 and COX-2 mRNA were observed in the testis, 
pancreas, kidney, liver, thymus, and brain. 
Cyclooxygenase; Prostaglandin synthase; Prostaglandin; Thromboxane 
1. INTRODUCTION 
The conversion of arachidonic acid to prostaglandin 
H, is catalyzed by cyclooxygenase (COX; prostaglandin 
H synthase/cyclooxygenase; EC 1.14.99.1) which has 
recently been shown to exist in at least two isoforms, 
termed COX-1 and COX-2 [l-9]. The COX-1 enzyme 
was originally characterized from ovine and bovine ve- 
sicular glands (reviewed in [lO,l 11) and the cDNA and 
gene encoding a human platelet/erythroleukemia cell 
COX-1 have been isolated [ 1 ,121. Several groups have 
observed that a second isoform of COX (termed COX- 
2) is inducible by a variety of agents including mitogens, 
cytokines, phorbol esters and serum in murine, chicken, 
and human cell lines [2,3,5-9,13-171. Comparison of the 
recently cloned human COX-2 cDNA to the human 
COX-1 cDNA revealed that it has 64% overall amino 
acid sequence identity to human COX-1 [1,2]. Both 
human COX-1 and COX-2 cDNAs encode enzymati- 
tally active cyclooxygenases which are inhibited by non- 
steroidal anti-inflammatory drugs such as indometha- 
tin [1,2]. 
COX-1 protein and mRNA has been demonstrated 
in many cell lines and in virtually all mammalian tissues 
(reviewed in [lo]). The distribution of COX-2 mRNA 
appears to be much more restricted with its expression 
detected in a limited number of cell lines [2,3,5-9,13- 
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171. Since there is no data available on the tissue distri- 
bution of COX-2 in man, we have undertaken an anal- 
ysis of the tissue distribution of human COX-2 mRNA. 
We have used both Northern and reverse transcriptase- 
polymerase chain reaction (RT-PCR [ 18,191) techniques 
since previous studies have demonstrated the difficulty 
of detecting COX mRNA by Northern analysis [20-241. 
Our analyses suggest that both COX-1 and COX-2 
mRNAs are normally co-expressed at low but detecta- 
ble levels in most human tissues. 
2. EXPERIMENTAL 
2.1. Materials 
The human COX-1 (hCOX-1) cDNA was a gift from Dr. C. Funk 
[l]. The human COX-2 (hCOX-2) cDNA was kindly provided by Dr. 
B. Kennedy (Merck Frosst Centre for Therapeutic Research, Mon- 
treal, Que., Canada) and had been generated by RT-PCR using ol- 
igonucleotides based on the published hCOX-2 cDNA sequence [2]. 
A 1.1 kb cDNA coding for human glyceraldehyde-3-phosphate dehy- 
drogenase (GAPDH: [25]) was purchased from Clontech Laboratories 
(Palo Alto, CA). Human poly(A)’ RNA samples were prepared by 
Clontech from the following sources: adult female was the source for 
lung, uterus, liver, stomach and small intestine RNAs; mammary 
gland RNA was from a pool of 2 nonlactating females; male adult was 
the source for brain, pancreas, kidney and liver RNA: prostate RNA 
was a pool of five adult males; thymus RNA was from a three year 
old male. Single stranded RNA molecular weight markers were pur- 
chased from GIBCO-BRL (Burlington, Ont., Canada). 
2.2. Northern blot analysis 
Three micrograms of poly(A)+ RNA isolated from human stomach 
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and small intestine (Clontech) were separated in a 0.8% agarose gel 
containing 6.6% formaldehyde and transferred to a nitrocellulose 
membrane by overnight capillary blotting in 20 x SSC (1 x SSC is 0.15 
M NaCl, 0.015 sodium citrate, pH 7.0). The blots were baked at 80°C 
for 2 h and then prehybridized for 5 h at 42°C in 4 x SSPE (lx SSPE 
is 0.15 M NaCl, 0.01 M sodium phosphate, and 0.001 M EDTA, pH 
7.4) 8 x Denhardt’s solution (1 x Denhardt’s is 0.02% Ficoll, 0.02% 
bovine serum albumin, 0.02% polyvinylpyrrolidone), 100 &ml soni- 
cated calf thymus DNA, 50% formamide, and 2% SDS. The blot was 
hybridized for 18 h at 42°C in fresh prehybridization solution contain- 
ing 1 x lo6 cpm/ml of 32P-labeled DNA probe. The probes were pre- 
pared by labeling purified DNA fragments using a random hexamer 
priming kit ([26]; United States Biochemical, Cleveland, OH). The 
hCOX-1 and hCOX-2 probes were 1.8 kbp DNA fragments contain- 
ing only the respective coding sequences but not the 5 or 3’ untrans- 
lated flanking sequences [1,2]. Following hybridization the blots were 
washed three times for 20 min at 55°C in 0.2 x SSC containing 0.1% 
SDS and then exposed to Kodak XAR-5 film, with two intensifying 
screens at -8O‘C for l-6 days. 
2.3. RT-PCR quantitation of &WA 
To identify tissues expressing mRNA for COX-1 and COX-2, exact 
primers were synthesized based on an analytical RT-PCR procedure 
developed for human cyclooxygenases [2,20]. For hCOX-1, primers 
were 5’-TGCCCAGCTCCTGGCCCGCCGCTT-3’ (a 24-mer sense 
oligonucleotide at position 516) and 5’-GTGCATCAACACAGG- 
CGCCTCTTC-3’ (a 24-mer antisense oligonucleotide at position 819). 
giving rise to a 303 bp PCR product [1,2]. For hCOX-2, primers were 
5’-TTCAAATGAGATTGTGGGAAAATTGCT-3’ (a 27-mer sense, 
oligonucleotide at position 573) and 5’-AGATCATCTCTGCCT- 
GAGTATCTT-3’ (a 24-mer antisense oligonucleotide at position 
878), giving rise to a 305 bp PCR product [1,2]. Primers were also 
synthesized to amplify the cDNA encoding GAPDH, a constitutively 
expressed gene, as control. For GAPDH, primers were 5’-CCACC- 
CATGGCAAATTCCATGGCA-3’ (a 24-mer sense oligonucleotide 
at position 216) and 5’-TCTAGACGGCAGGTCAGGTCCACC-3 
(a 24-mer antisense oligonucleotide at position 809), giving rise to a 
593 bp PCR product [25]. Poly(A)’ RNA (1 pg) from each of twelve 
human tissues was converted to single-stranded cDNA using Moloney 
murine leukemia virus reverse transcriptase and 2.5 PM of random 
hexamers according to the manufacturer’s protocol (GeneAmp RNA 
PCR kit, Perkin Elmer Cetus, Norwalk, CT). The cDNA samples were 
then split into three equal aliquots for amplification by the specific 
primers for COX-1, COX-2 and GAPDH [2]. PCR reactions were 
carried out in a buffer containing 10 mM Tris-HCl (pH 8.3), 50 mM 
KCl, 2.5 mM MgCl,, 0.2 mM deoxynucleotides triphosphates and 0.5 
BM primers using a cycling program of 94°C for 1 min, 55°C for 1 
min, and 72°C for 1 min in a Perkin Elmer Cetus 9600 thermal cycler. 
The RT-PCR quantitation was perfomed using two protocols estab- 
lished for the estimation of COX mRNA levels [2,20,22,24]. In the first 
RT-PCR protocol , following the twentieth, twenty-fifth, and thirtieth 
cycle an aliquot of each reaction was removed and stopped by the 
addition of EDTA to 10 mM [2]. In the second RT-PCR protocol, 
PCR was performed on two-fold serial dilutions of the reverse tran- 
scribed RNA [20]. In order to establish a standard curve and the limits 
of sensitivity, PCR was preformed on serial dilutions of known 
amounts of plasmids containing either hCOX-1 or hCOX-2 cDNA. 
PCR products were separated by electrophoresis n 1.2% agarose gels, 
visualized by ethidium bromide staining, blotted to nitrocellulose 
membranes by overnight capillary transfer in 10 x SSC [27]. 
2.4. Southern hybridizations 
Southern blot hybridizations were performed at 42°C for 6 h in a 
solution containing 6 x SSC, 5 x Denhardt’s, lOO&ml denatured calf 
thymus DNA, 0.1% SDS, 50% formamide, and 1 x lo6 cpm/ml of 
hybridization fluid of a ‘*P-labeled probe. The “P-labeled probes 
(specific activities of 1-3 X lo9 cpm@g DNA) were prepared by ran- 
dom hexamer priming [26] of the following DNA fragments: the COX- 
1 probe was a cDNA fragment coding for amino acids 173-271 of 
hCOX-1 [l]; the COX-2 probe was a cDNA fragment spanning amino 
acids 16&260 of hCOX-2 [2]; and the GAPDH probe was a cDNA 
fragment coding for amino acids 52-250 of hGAPDH [25]. The blots 
were washed three times in 0.2 x SSC, 0.2% SDS for 20 min at 55°C 
and then exposed to Kodak XAR-5 film for 3-120 min at 23°C. The 
mRNA levels were quantitated by cutting the portion of the nitrocel- 
lulose membrane corresponding to the autoradiographic bands and 
quantifying the bound radioactivity by liquid scintillation counting. 
To normalize the signals obtained from different RNA samples, the 
signal for GAPDH was used as an internal control for each sample 
with the signals for COX-1 and COX-2 normalized with respect to 
GAPDH. 
3. RESULTS 
3.1. Northern blot analysis 
In order to evaluate the sensitivity of Northern blot 
analysis for COX mRNAs, stomach and small intestine 
RNAs were examined (Fig. 1). Under high stringency 
hybridization conditions COX- 1 and COX-2 transcripts 
were detected in stomach and small intestine RNA 
using 3 pug poly(A)’ RNA and a 3 day autoradiographic 
exposure. In both stomach and small intestine, two 
COX-1 transcripts of approximately 3 kb and 5 kb were 
detected (Fig. lA), whereas a single 5 kb COX-2 tran- 
script was observed. Under the hybridization conditions 
we employed (6 x SSC, 50% formamide at 42°C) the 
COX-1 and COX-2 probes should not cross-hybridize 
as their cDNA coding sequences are only 64% identical 
[1,2]. Our results are in agreement with the size and 
number of human COX-I and COX-2 transcripts previ- 
ously observed [1,2]. The 3 kb COX-1 transcript has 
been cloned but the 5 kb COX-1 transcript remains 
f ‘( i 
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Fig. 1 Northern blot analysis of poly(A)’ RNA isolated from human 
stomach and small intestine for COX-1 and COX-2. Three pg of 
poly(A)’ RNA were loaded per lane, electrophoresed in a 0.8% aga- 
rose-6.6% formaldehyde gel, and transferred to a nylon membrane. 
The membranes were probed at high stringency (42°C. 50% forma- 
mide) with a “P-labeled COX-1 cDNA probe (panel A) or a “P- 
labeled COX-2 cDNA probe (panel B). The positions of single 
stranded RNA molecular weight standards are indicated at the left in 
kb. The autoradiogram was developed after a three day exposure. 
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Fig. 2 RT-PCR analysis of mRNA for COX-1 and COX-2 in human tissues. Detection of PCR products by Southern blot hybridization. 
Single-stranded cDNA converted from a variety of poly(A)’ RNA’s (250 ng; see Section 2 for sources of RNA) was used for PCR amplification 
with COX-1, COX-2 and GAPDH specific primers for 20,25, and 30 cycles. The PCR products were electrophoresed on 2.0% agarose gels, capillary 
blotted onto nitrocellulose membranes and probed with “P-random primer-labeled human COX-1, COX-2 or GAPDH probes using high stringency 
hybridization conditions (42°C 50% formamide). The expected fragments of 303, 305, and 593 base pairs for COX-1, COX-2, and GAPDH, 
respectively, are indicated. The higher molecular weight signals amplified from brain RNA samples result from genomic DNA contamination (see 
text for details). The relative amounts of each signal were determined by scintillation counting of the radioactivity of the excised bands, followed 
by normalization of each sample using expression of GAPDH as the standard [2,22,24]. 
uncharacterized [1,2]. It has been suggested that the 5 
kb transcript is a partially spliced COX-1 mRNA [l]. 
3.2. RT-PCR analysis 
Due to the relatively low abundance of COX RNAs 
in stomach and small intestine we used the more sensi- 
tive RT-PCR technique [2,20] to quantitate COX se- 
quences in mRNA from twelve different human tissues. 
As a control, the distribution of the constitutively ex- 
pressed GAPDH was also examined. Two methods to 
quantitate COX mRNA by RT-PCR have been devel- 
oped [2,20]. In the limited-cycle method, samples are 
removed from the PCR reaction at the twentieth, 
twenty-fifth, and thirtieth cycles to ensure that quantita- 
tion is done during the exponential phase of amplifica- 
tion [22,24]. In a second method described for the 
RTPCR quantitation of COX mRNA, the PCR is per- 
formed on serial dilutions of the cDNA reaction mix- 
ture with all samples removed at the same cycle number 
[20]. As shown in Fig. 2 for the limited-cycle PCR 
method, COX-1 and COX-2 PCR products of the ex- 
pected size were amplified from all tissues examined, 
including lung, uterus, testis, pancreas, kidney, liver, 
thymus, prostate, mammary gland, stomach, and small 
intestine, after 25 or 30 cycles of amplification. All RNA 
samples yielded a GAPDH-specific PCR product de- 
monstrating that all RNA’s were sufficiently intact to 
support RT-PCR (Fig. 2). Faint signals for COX-1 and 
COX-2 were seen in brain only after 30 cycles of ampli- 
fication and a lo-fold over-exposure of the autoradi- 
ograph shown in Fig. 2. Brain RNA samples also gave 
rise to an additional COX-1 and COX-Zhybridizing 
product of approximately 1.0 kb (Fig. 2). These signals 
result from genomic DNA contamination of the poly 
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(A)’ RNA preparation since hybridizing products of 1 .O 
kb were also observed in PCR samples using equivalent 
samples of brain poly(A)’ RNA that were not treated 
with reverse transcriptase as template. The higher mo- 
lecular weight PCR products were also observed when 
purified human genomic DNA was used as the template 
(data not shown). The primer sets for COX- 1 and COX- 
2 are all located in different exons in order to distinguish 
the amplification of RNA from DNA templates. Ampli- 
fication of the genomic COX-1 and COX-2 intron-con- 
taining sequences yield higher molecular weight PCR 
products [1,2,12]. 
In order to more accurately quantitate the absolute 
level of COX mRNA, the RT-PCR quantitation was 
repeated using a serial dilution RT-PCR method [20]. 
For each tissue, poly(A)’ RNA was reverse transcribed 
and COX-1 and COX-2 specific PCR’s were performed 
on serial dilutions of the cDNA. In parallel, PCR ampli- 
fication was carried out for 25 cycles on serial dilutions 
of known quantities of cloned COX-1 and COX-2 
cDNAs to establish standard amplification curves and 
sensitivity limits. An example of quantitation of COX 
mRNAs in kidney is shown in Fig. 3. The amplification 
curves for the diluted COX-1 and COX-2 cDNAs 
showed that at twenty-five cycles of PCR the logarith- 
mic phases of the amplifications were obtained when up 
to 10,000 cDNA molecules were used as the starting 
template and that both COX-1 and COX-2 sequences 
were amplified with about the same efficiency (Fig. 3C). 
The lower limit of senstitvity for 25 cycles of PCR was 
about 10 molecules of input COX-1 or COX-2 cDNA 
template; Approximately 6,000 COX- 1 and 2,000 COX- 
2 transcripts were present in 100 ng of the kidney 
poly(A)’ RNA sample (Fig. 3). Quantitative RT-PCR 
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Fig. 3 Quantitative analysis by RT-PCR of COX-1 and COX-2 
mRNA sequences in serially diluted human kidney RNA. (A, B) 
Autoradiograms of COX-1 and COX-2 PCR products following am- 
plification for 25 cycles of serial I:2 dilutions of 1 x lo6 plasmids 
containing either COX-1 (panel A , lanes l-8) or COX-2 (panel B, 
lanes l-8) cDNAs and amplification of serial 2-fold dilutions of 250 
ng of reverse transcribed kidney poly (A)* RNA to obtain COX-1 
(panel A, lanes 1 l-17 ) and COX-2 (panel B, lanes 1 l-17) specific PCR 
products. Lanes 9 and 18 in panels A and B are control reactions 
carried out in the absence of added template. Samples of the PCR were 
separated on a 2% agarose gel, Southern blotted with COX-1 or 
COX-2 radiolabeled cDNA probes, and then analyzed by autoradi- 
ography. (C) PCR amplification curves of serial dilutions of known 
quantities of plasmids containing either COX-1 (0) or COX-2 (0) 
cDNAs or kidney poly(A)’ RNA using specific COX-1 (w) and COX-2 
(0) oligonucleotide primers. The autoradiograms from panels A and 
B were used to locate the positions of the bands on the nitrocellulose 
filters, the respective areas were cut out, and the radioactivity was 
quantitated by liquid scintillation counting. The radioactivity was 
plotted against the amount of input RNA or the number of input 
plasmid cDNA molecules. The standard amplification curves for the 
plasmid-encoded COX-1 and COX-2 cDNAs represents four experi- 
ments using 1:2 and 1:lO serial dilutions of the template. 
using serial dilution of the reverse transcribed poly(A)’ 
RNA was performed for eleven other tissues; the results 
of the quantitative analysis are shown in Table I. COX- 
1 and COX-2 mRNA s were both co-expressed to high 
levels in the prostate, whereas high levels of COX-2 but 
not COX-1 mRNAs were present in the lung. Interme- 
diate and approximately equivalent levels of both COX- 
1 and COX-2 mRNA were present in stomach, small 
intestine, uterus, and mammary gland. Lower but ap- 
proximately equivalent levels of both COX- 1 and COX- 
2 were observed in the thymus, liver, testis, kidney, and 
pancreas with the lowest levels of COX-1 and COX-2 
observed in the brain. 
4. DISCUSSION 
Prostaglandins and thromboxane A, have been impli- 
cated as important mediators of various pathological 
processes including pain, inflammation, fever and uter- 
ine contractions. In addition prostaglandins are thought 
to have important physiological roles, for example in 
the maintenance of normal gastric function and renal 
blood flow. The mechanism of action of non-steroidal 
anti-inflammatory drugs is through inhibition of cy- 
clooxygenase and because of this such compounds have 
important therapeutic effects as well as mechanism- 
based side effects (e.g. gastric ulceration). It appears 
that conventional cyclooxygenase inhibitors, such as in- 
domethacin, have little selectivity for either human 
COX-1 or COX-2 (P. Vickers unpublished results). 
There has thus been speculation as to whether selective 
inhibitors of either COX- 1 or COX-2 might have useful 
therapeutic effects with a diminished ability to induce 
mechanism-based side effects. In particular the discov- 
ery that the expression of COX-2 is highly inducible and 
selective suggests that this enzyme may be of particular 
importance in, for example, either hormonally-induced 
uterine contractions, as seen in dysmenorrhea, or cytok- 
ine-induced prostaglandin production, as seen in in- 
flammatory joint diseases. It is thus of considerable 
interest to investigate the distribution of COX-1 and 
COX-2 in human tissues. 
The present study used human tissues, mainly ob- 
tained from trauma victims, which presumably are un- 
stimulated and not subject o induction. Although these 
studies did not address the inducibility of COX mRNA 
in human tissues, it appears that all the tissues tested 
contained constitutively expressed levels of both COX-1 
and COX-2 mRNA . Of particular interest was the pres- 
ence of both forms of mRNA in stomach and small 
intestine in view of the importance of gastric damage as 
the major mechanism-based side effect of non-steroidal 
anti-inflammatory drugs. It should be noted, however, 
that as observed in a variety of mammalian cell lines, 
the level of COX-2 may be selectively increased over 
159 
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Table I 
COX-1 and COX-2 mRNA levels in human tissues 
Molecules mRNA/lOO ng 
poly(A)+ RNA 
mRNA species 
> 50,000 
25,000-50,000 
12,500-25,000 
lOOO-12,500 
100-1000 
cox-1 
prostate 
uterus 
small intestine 
mammary gland 
stomach 
lung 
thymus, liver 
kidney, testis 
pancreas 
brain 
cox-2 
prostate 
lung 
uterus 
small intestine 
mammary gland 
stomach 
thymus, liver 
kidney, testis 
pancreas 
brain 
20-fold by exposure of the cells to mitogens and cytok- 
ines with little effect on COX-1 mRNA levels [2,3,5- 
8,11,13-l 71. For example, in human umbilical vein en- 
dothelial cells, monocytes, vascular smooth muscle cells 
and foreskin fibroblasts, low levels of both COX-1 and 
COX-2 transcripts are expressed, while after stimula- 
tion of the cells with phorbol myristic acid the level of 
COX-2 mRNA was selectively and dramatically in- 
creased over 20-fold [2]. 
There is limited information available on the tissue 
distribution of COX-2. The expression of COX-2 
mRNA in mice is reported to be both tissue-specific and 
developmentally regulated [28]. Murine COX-2 was de- 
tectable in the newborn thymus and kidney and in the 
adult brain, lung and testis; COX-2 mRNA was not 
observed in either the murine heart, spleen, muscle or 
liver [28]. Our studies are in agreement with the mouse 
tissue distribution study [28] except we detect COX-2 in 
the human adult liver and very low levels of COX-2 
mRNA prepared from human whole brain. The low 
levels of COX-1 and COX-2 mRNA we observed in 
RNA extracted from whole brain suggests that the COX 
protein is also present at low levels or that COX expres- 
sion is not uniform in the brain. Immunohistochemical 
studies of monkey and ovine brain tissue have demon- 
strated cyclooxygenase-immunoreactive protein ex- 
pressed only in specific cell types and areas of the brain 
[29,30]. The highest levels detected in the present study 
were observed in the prostate, consistent with the high 
levels of prostaglandins present in seminal fluid. 
In conclusion these studies show that in a variety of 
human tissues both COX-1 and COX-2 mRNA are 
present. It will clearly be important to relate these levels 
to the expression of the protein and active enzyme in the 
various tissues and it will also be of considerable interest 
to see if these ratios are dramatically disturbed in vivo 
following, for example, hormonal or inflammatory 
stimuli. 
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